JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma
Abstract
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose.
Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups.
Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups.
Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.

Keywords : Lymphoma, autologous hematopoietic stem cell transplantation, CD34+ cell, engraftment, survival

Download Article


1. Wang Sophia S. Epidemiology and etiology of diffuse large B-cell lymphoma. In: Seminars in hematology. WB Saunders, 2023. p. 255-266.
2. Munir F, Hardit V, Sheikh IN, et al. Classical Hodgkin lymphoma: from past to future—a comprehensive review of pathophysiology and therapeutic advances. Int J Mol Sci. 2023;24(12):10095. doi:10.3390/ijms 241210095
3. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45. doi:10.3322/caac.21871
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med. 1995;333(23):1540-1545. doi:10.1056/NEJM199512073332305
5. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065-1072. doi:10.1016/j.bbmt.2006.06.006
6. Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217-226. doi:10.1007/s11899-017-0382-1
7. Berber İ, Sarici A. Hodgkin lenfomada epidemiyoloji ve etiyoloji. Hodgkin Lenfoma. 2020:1-5.
8. Lemieux C, Ahmad I, Bambace NM, et al. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leuk Res. 2019;79:75-80. doi:10.1016/j.leukres.2019.01.002
9. Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(8):1479-1487. doi:10. 1016/j.bbmt.2015.04.004
10. Sarıcı A, Erkurt MA, Kuku İ, et al. The effect of comorbidity on survival and collected CD34+ cell counts in autologous hematopoietic stem cell transplant patients. Transfus Apher Sci. 2022;61(1):103296. doi:10.1016/j.transci.2021.103296
11. Regalado-Artamendi I, García-Fasanella M, Medina L, et al. Age, CD34+ cell dose, conditioning and pre-transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation. Vox Sanguinis. 2023;118(8):681-689. doi:10.1111/vox.13486
12. Moreb JS, Lantos L, Chen F, et al. The effect of mobilizing large numbers of CD34+ cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation. Transfus Apher Sci. 2023;62(6):103787. doi:10.1016/j.transci.2023.103787
13. Sarıcı A, Erkurt MA, Bahçecioğlu ÖF, et al. Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma-single center experience. Transfus Apher Sci. 2021;60(4):103127. doi:10. 1016/j.transci.2021.103127
14. Turunen AS, Kuittinen O, Kuitunen H, et al. CD34+ cell mobilization, autograft cellular composition and outcome in mantle cell lymphoma patients. Transfus Med Hemother. 2023;50(5):428-437. doi:10.1159/ 000531799
15. Balint MT, Bila J, Balint B, et al. Influence of applied CD34+ cell dose on the survival of Hodgkin’s lymphoma and multiple myeloma patients following autologous stem cell transplants. Vojnosanitetski Pregled. 2020;77(8):844-851. doi:10.2298/VSP180808160T
16. Hassan MN, Fauzi HM, Husin A, et al. Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: factors influencing engraftment. Oman Med J. 2019;34(1):34-43. doi:10. 5001/omj.2019.06
17. Lutfi F, Skelton IV WP, Wang Y, et al. Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. Hematol Oncol Stem Cell Ther. 2020;13(1):23-31. doi:10.1016/j.hemonc. 2019.08.003
18. Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood. 2011;117(12):3277-3478. doi:10.1182/blood-2010-08-300491
19. Yamaguchi J, Chinen Y, Takimoto-Shimomura T, et al. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2019;60(14):3434-3441. doi:10.1080/10428194.2019.1636982
20. D’Rozario J, Parisotto R, Stapleton J, Gidley A, Owen D. Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation. Transfus Apher Sci. 2014;50(3):443-450. doi:10.1016/j.transci.2014.02.021
21. Sarici A, Erkurt MA, Kuku I, et al. Selection of the mobilization regimen in lymphoma patients: a retrospective cohort study. Transfus Apher Sci. 2021;60(5):103251. doi:10.1016/j.transci.2021.103251
22. Fernandez-Sojo J, Cid J, Azqueta C, et al. Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2022;57(8):1341-1343. doi:10.1038/s41409-022-01722-6
23. Partanen A, Turunen A, Valtola J, et al. Loss of CD34+ cells and effect of the number of viable cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery, progression-free survival and overall survival in NHL patients after autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2023;23(11):e428-e435. doi:10.1016/j.clml.2023.08.009
Article available in :
Volume 4, Issue 2, 2026
Page : 47-52
https://doi.org/10.51271/JCHOR-0081
Article Information
Received : 06 Mar 2026
Accepted : 22 Nis 2026
Published : 18 May 2026
Corresponding Author :

Ahmet Sarıcı: Department of Hematology, İnönü University, Malatya, Turkiye

[email protected]
Citation : Sarıcı A, Erkurt MA, Kuku İ, et al. CD34? cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma. J Curr Hematol Oncol Res. 2026;4(2):47-52. doi:10.51271/JCHOR-0081

Read: 127
Download : 57
Cited: 0
_Footer